Lexicon Announces The Launch Of Aboutcarcinoid.com To Provide Carcinoid Syndrome Disease Education To Patients, Caregivers And Physicians

THE WOODLANDS, Texas, June 2, 2016 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the launch of www.aboutcarcinoid.com to provide carcinoid syndrome disease education to patients, caregivers and physicians.  Concurrent with the launching of the website, Lexicon is also working with seven leading national and regional patient advocacy groups to conduct the Carcinoid Syndrome Impact Survey, which is designed to improve understanding of the impact that carcinoid syndrome has on patient lives.  Additional information on the survey can be found at www.aboutcarcinoid.com.

Aboutcarcinoid.com was created with input from a diverse group of carcinoid syndrome patients, their loved ones and the physicians who treat them.  The website is designed to raise awareness of carcinoid syndrome and provide practical information and tools for patients and physicians.  Aboutcarcinoid.com is intended for educational purposes only and is not intended to provide medical advice.  Every person's medical situation is unique and any questions should be directed to a healthcare professional.

"Carcinoid tumors are generally slow-growing.  Therefore, while tumor control is particularly important, maintaining social, emotional, and physical functionality is paramount in treating patients with carcinoid syndrome," said Jonathan Strosberg, M.D., Lead of the Neuroendocrine Tumor Division and Associate Professor at H. Lee Moffitt Cancer Center. "Many patients dramatically alter their daily lives to accommodate the effects of carcinoid syndrome and patients may experience urgent and debilitating diarrhea or even lose complete control of bowel function."

The Carcinoid Syndrome Impact Survey is unique in that it brings together the collective efforts of seven leading national and regional patient advocacy groups:

• Carcinoid Cancer Foundation (CCF)
• Neuroendocrine Cancer Awareness Network (NCAN)
• Neuroendocrine Tumor Research Foundation (NETRF)
• Healing Net Foundation
• Los Angeles Carcinoid Neuroendocrine Tumor Society (LACNETS)
• NorCal CarciNET Community
• Big Apple NETs

"By working together, it is our shared hope to shine a much needed spotlight on the detrimental effects that carcinoid syndrome has on patient lives, while raising awareness and understanding of this syndrome in the physician communities," said Grace Goldstein, Chief Operating Officer of Carcinoid Cancer Foundation, a national patient advocacy and information organization.

About Carcinoid Syndrome

Carcinoid syndrome is a rare disease affecting thousands of cancer patients with metastatic neuroendocrine tumors that have spread to the liver and other organs from the gastrointestinal tract. Overproduction of serotonin within these metastatic neuroendocrine tumor cells is a driver of carcinoid syndrome, which is characterized by debilitating diarrhea, facial flushing, abdominal pain, heart valve damage and other serious consequences.  The severe and unpredictable diarrhea associated with carcinoid syndrome has a profound impact on cancer patients' lives, often preventing them from participating in daily activities.

About Lexicon

Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through its Genome5000™ program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has a pipeline of promising drug candidates in clinical and pre-clinical development in oncology, diabetes and metabolism. For additional information please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the risk that clinical studies of its drug programs may be halted, delayed or otherwise not demonstrate safety or efficacy, the risk that the FDA and other regulatory authorities may not grant regulatory approval of its drug programs in accordance with Lexicon's currently anticipated timelines or at all, and the risk that such regulatory approvals, if granted, may have significant limitations on the approved use of its drug candidates. As a result, Lexicon's drug candidates may never be successfully commercialized. Other risks include Lexicon's ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its drug candidates, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.